Innovation and the Future of Pharmacovigilance

Embark on a captivating journey with Nicole Baker, the pioneering CEO of Biologit, as she shares her remarkable transition from academia to the forefront of pharmacovigilance on Truliant Talks. Nicole's narrative is not just about her personal evolution but also serves as an illuminating guide through the labyrinth of safety regulations and drug monitoring. Her candid conversation is a deep dive into the importance of patient safety, the impact of regulatory shifts, and the ever-present need for industry adaptability. We examine the significance of professional networks and the influence of major events like Brexit, providing an insightful look at how these factors have reshaped the European pharmacovigilance landscape.As technology becomes increasingly intertwined with pharmacovigilance, Nicole lays out her experiences in harnessing AI to revolutionize the field. She reflects on the challenges of setting up a department during Brexit and the subsequent founding of a consultancy aimed at developing accessible AI models for the industry. We unravel the intricacies behind AI and automation, discussing their roles in improving the efficiency and accuracy of adverse event detection. The synergy between pharmacovigilance professionals and technology is spotlighted, as we explore the cautious optimism surrounding AI's potential and the journey from skepticism to acceptance within the industry.Finally, we turn our attention to the future, speculating on how integration within pharmacovigilance could transform safety data analysis and application. We discuss the necessity of a broader perspective in adverse event reporting, touching upon the current inefficiencies and the potential for systems that ensure data accuracy and consistency. With Nicole's valuable insights, we conclude with aspirations for these advancements to materialize over the next five years, revolutionizing how we understand and manage drug safety. Tune into Truliant Talks for an episode that promises to broaden your horizons on the pivotal role of pharmacovigilance in healthcare.

Embark on a transformational trek with Bill Ringbloom, AstraZeneca's Head of Global Patient Safety Technical Solutions as he shares his unconventional career trajectory from the financial chaos of 2008 to the cutting edge of pharmacovigilance. With a treasure trove of experience spanning IT, finance, and project management, Bill's insights shed light on the value of adaptable skill sets in the ever-evolving pharmaceutical domain. Tune in and uncover how the fusion of these diverse abilities is not just enhancing global patient safety but is also shaping the strategic role of IT within the healthcare juggernaut.In the heart of our exchange, Bill dissects the intricate dance between finance and life sciences, proving that the two are more intertwined than one might assume. The conversation reveals how the flexibility of IT not only supported AstraZeneca through the pandemic but also bolstered the rollout of their vaccine. Listen closely as we navigate the thought-provoking parallels that bridge two seemingly disparate worlds, reinforcing the significance of financial prowess in steering the ship of innovation amidst a sea of stringent industry demands.The episode culminates with a deep dive into the frontiers of data strategy and the monumental efforts in cloud migration for drug safety. Bill elucidates the vision for a 'data supermarket'—where data is not just abundant but actionable—and the intricate balance necessary when enhancing surveillance to serve scientific use cases. Grasp the complexities of IT decisions that are transforming patient safety and R&D processes as we explore how AstraZeneca is steering towards predictive analytics in pharmacovigilance, all while navigating the need for efficiency and the pursuit of scientific precision.

Embark on an enlightening expedition, as we navigate the vital intricacies of pharmacovigilance and risk management alongside Tom Nichols, zoologist turned PV aficionado and Director of Drive Phase PV. Tom regales us with his unexpected but inspiring foray into the world of drug safety, stemming from a keen interest in epidemiology. His captivating tales underscore the importance of PV in delivering life-saving therapies to market, particularly through his work with Clozapine, an anti-psychotic medication. This conversation is a testament to PV's dual role as both a guardian of public health and a strategic ally in expediting breakthrough medical treatments.Tom then delves into the nuances of integrated clinical trial sponsorship and how this model encourages collaboration across the pharmaceutical landscape. Reflecting on my own career trajectory, he offer's a candid comparison of working within the close-knit fabric of clinical research versus the challenges posed by outsourcing, providing a glimpse into the dynamic nature of our industry.As the journey concludes, Tom explores the landscape of future pharmacovigilance strategies, where the deployment of AI could revolutionize patient safety protocols, and the delicate balance between swift drug access and thorough post-market analysis is ever-present. Tom's insights, coupled with moments of passionate discourse, have been nothing short of invigorating. Join us for a conversation that promises not only to inform but to inspire a deeper appreciation of pharmacovigilance.

Discover the intricate world of pharmacovigilance as Colleen Walsh, the Vice President of Global Patient Safety Operations at Alnylam, unveils her personal journey through the ever-evolving landscape of patient safety. In this enthralling episode of Innovation and the Future of Pharmacovigilance, I sit down with Colleen to unravel the complexities she's encountered, from the pivotal Tysabri incident at BioGen to leading R&D compliance at Alexion. Her story is a testament to the resilience required in the face of regulatory upheavals and the innovative spirit needed to navigate from clinical trials to post-market safety.In a field where the stakes are as high as the patients' lives, Colleen sheds light on the arduous task of merging companies within the rare disease sector, specifically the AstraZeneca acquisition of Alexion. Through her insights, we gain an understanding of the delicate balance between patient support programs and the scrutiny of global pharmacovigilance regulations. Colleen's expertise reveals the pressing need to bridge the gap between regulatory intent and its real-world application, ensuring that patient safety remains paramount while fostering a culture of innovation.Our discussion veers into the future of pharmacovigilance technology, examining how AI could revolutionize the industry yet poses unique challenges for both behemoths and fledgling companies in the pharmaceutical world. Colleen proposes an intriguing shift in perspective, advocating for pharmacovigilance to transition from a cost burden to a revenue generator by incorporating safety measures early in drug development. Join us on this episode as we probe into a future where pharmacovigilance not only safeguards patients but also drives value and progress in the realm of medicine.

Embark on an insightful exploration of pharmacovigilance with me, Indy Ahluwalia, as I sit down with industry trailblazer Rishi Chopra on Truliant Talks. Witness the fascinating narrative of Rishi's transition from biochemistry academia to becoming an instrumental figure in the pharmacovigilance space. His candid recount of the early days at Roche, where a nurturing community played a crucial role in his growth, sets the stage for a discussion full of personal anecdotes and pivotal moments that define a career. We delve into the essence of mentorship and the power of connections that transcend roles, highlighting Rishi's journey from his initial foray into the field to his current influential position.Prepare to be inspired as Rishi unfolds the map of his leadership voyage, from establishing compliance frameworks to lecturing at universities, blending academic rigor with invaluable industry experience. His tales from the trenches at Otsuka, Biogen, and now CSL showcase the continuous learning and the unyielding pursuit of patient safety under the mentorship of industry luminaries. The chapter not only sheds light on overcoming challenges and celebrating triumphs but also on the diverse cultural insights gained from working with global teams.As the healthcare landscape evolves, so do the tools and technologies shaping its future. Rishi lends his global perspective on the burgeoning role of artificial intelligence and the potential of social media in revolutionizing patient data collection. The conversation turns to the frontiers of personalized medicine and the anticipation of new roles that will merge technology with patient care. Our episode culminates with an eye on harmonizing global regulations, ensuring that, through collaboration and innovation, patient safety remains at the heart of pharmacovigilance. Join us for a riveting dialogue that promises to leave you enlightened and excited about the future of healthcare.

Embark on a journey through the dynamic world of pharmacovigilance with Michael Braun-Boghos, the seasoned Senior Director of Safety Strategy at Oracle. In our first  episode of the season, Michael unpacks his three-decade odyssey from the analog days of adverse event forms to the digital frontier of pharmacovigilance. As we traverse his career landscape, the evolution from paper trails to strategic IT roles unfolds, highlighting pivotal shifts and the integrative prowess of systems like Argus. Michael's anecdotes from the merge that birthed Astellas to the strategic tides at Relsys before its acquisition by Oracle offer a rare glimpse into the industry's transformation.This episode is a deep dive into the sea of innovation that is healthtech, where the currents of patient safety and regulatory compliance meet. Michael defends the gradual innovation ethos that Argus embodies within the high-stakes realm of pharmacovigilance, underscoring its necessity amidst an industry where risk is a constant companion. Our discussion also sails into the partnership between software providers and health authorities, the burgeoning concept of 'touchless cases', and the cautious yet crucial adoption of AI. Prepare to be enlightened by our collaborative narrative that stresses the importance of evolving procedures to harness technology's full potential without sacrificing safety.Looking towards the horizon, we cast a net over the transformative impact of automation and AI on pharmacovigilance. Michael paints a future where Argus and similar tools streamline processes, and the integration of real-world data is set to revolutionize drug safety monitoring. We tackle the utilization of diverse data sets, from electronic health records to the untapped vistas of social media, and discuss how this influx of information is carving a path for precision in pharmacovigilance. Michael's personal reflections on the intrinsic rewards of contributing to global health safety, coupled with an exploration of the precision needed for enhanced patient outcomes, brings our episode to a close, leaving listeners with a profound understanding of the commitment to innovation and patient safety that defines the field's future.

Prepare to have your perceptions of pharmacovigilance revolutionized as we're joined by the trailblazing co-founders of Truliant Consulting. We're peeling back the layers of AI's profound impact on the pharmaceutical industry, revealing how 2023's tech leaps are changing the game for drug safety. From the fascinating convergence of wearables and social media data to the necessity of keeping a laser focus on patient safety, this episode is a treasure trove of insights into the tools and success stories shaping the future of medicine. Navigating the complexities of global regulatory landscapes, we dissect how companies are staying agile amidst an ever-changing field of rules and regulations. As we explore the tectonic shifts in the industry, illuminated by Pfizer's strategic acumen, our guests from Truliant share their wisdom on preparing for growth and maintaining efficiency in pharmacovigilance practices. This discussion is a must-listen for those keen on understanding the critical balance between innovation and compliance in the pharmaceutical world.As we chart a course towards 2024, we're not just predicting the future; we're sketching the blueprint of tomorrow's pharmacovigilance landscape. Discover how Integrated Risk Management Plans and patient feedback are set to become pivotal in the quest for enhanced drug safety. And with the spotlight on the potential of large language models, this episode offers a crystal ball view of the experiments and breakthroughs that lie just over the horizon. Tune in for a dose of foresight infused with the expertise of Truliant Consulting's visionaries, where the promise of progress in pharmacovigilance beckons.

Today's conversation comes alive with Tony De Sousa, the Global Head of Countries and Regions at Novartis, leading the discourse on a fascinating journey through the world of pharmacovigilance. Tony's intriguing journey from nursing to becoming a significant player in one of the world's largest pharmaceutical companies is sure to captivate you. We delve deep into the evolution of PV, contemplating the influence of European regulations and the complexities of leading a global team.But that's not all. We also engage in a spirited discourse him being a global leader from the pharmaceutical industry. It provides an enlightening perspective on how personal experiences with cultural shocks have continuously shaped his leadership approach. We journey through the impacts of COVID-19 on work and life, leading to a shift in priorities. He also shares some invaluable insights into the increasingly complex regulatory environment in various regions, and how his company has succeeded in preparing for PV inspections.Rounding off our conversation, we begin to examine the future of PV and the exciting role that artificial intelligence (AI) may play in this domain. The conversation highlights the current challenges and limitations of AI in PV while emphasizing the importance of risk management in patient safety. Finally, Tony offers his insights on the future of PV, the marriage of PV with data mining and the need for regulatory support for AI advancements. Don't miss out on this riveting conversation that provides a sneak peek into the future of PV.

Ever wondered how a company navigates the complexities of Pharmacovigilance (PV)? Catherine Kenny, managing partner and co-founder of Signal Pharma Experts, takes us on an enlightening journey through it all. With years of experience spanning from a generics company to a director and head of Benefit Risk at Diamond Pharma Services, Catherine shares her invaluable insights into the intriguing world of PV.Does the prospect of smaller firms utilizing AI, in the face of budgetary and resource limitations, seem daunting to you? Let’s take a look at it from a different angle. Imagine these firms joining forces to tackle larger safety database vendors - interesting, isn't it? Our discussion with Catherine brings in unique perspectives about managing regulatory inspections, project planning, and documentation. Plus, we emphasize on the oft-overlooked yet vital aspect of team spirit between departments in smaller firms. Catherine unveils the realities of running a risk management department in a small company, underscoring the indispensability of real-world data, risk minimization, and signal detection. So buckle up for a thought-provoking conversation that uncovers a spectrum of insights into the world of PV.

Imagine stepping into the world of pharmacovigilance with Sue Rees, founder of Sue Rees Consultancy, who has graced the industry for over three decades. As we stroll down memory lane, we relive Sue's fascinating progression from her rookie days at Smith, Kline & French's adverse events department to her critical QPPV roles across the continents. We unravel the compelling narrative of how Brexit prompted Sue's entrepreneurial journey and her contributions to the education sector.Together with Sue, we traverse through the contrasting paths taken by the FDA and the EMA, and delve into the divergent experiences of countries at varying stages of their PV journey. We also contemplate the ripple effects of the UK's EMA exit on its international reputation. Tune in as we contemplate the future of safety in organizations and the potential role of AI in diminishing manual case processing. We investigate the heightened emphasis on safety brought forth by the COVID-19 pandemic and explore effective delegation of responsibility within organizations. Let's tap into Sue's wisdom on the emerging trends of data gathering and legislation, and how the evolving regulations are reshaping career roles. As we peer into the future, we'll consider how technology could revolutionize data gathering, allowing us to concentrate on the clinical and scientific aspects of legislation.

Feeling intimidated by the thought of AI transforming the world of pharmacovigilance? Join us as we sit down with Fraser McCullum, founder of Imagine Pharmacovigilance Limited, who has spent over 20 years navigating the dynamic landscape of this industry. From his time as a bench scientist to establishing his own company, Fraser offers an insightful perspective on case processing to signal detection, and the future of risk management in pharmacovigilance. Our conversation also delves into the feared impact of AI on the conservative PV industry. Fraser clears the air on some widespread misconceptions and provides reassurances about the supposed threat of job loss due to AI. We also explore the increasing role of regulatory oversight in the age of Software as a Service (SaaS), and discuss how pharma companies must adapt to this new reality.We wrap up with an in-depth discussion on the future of pharmaceutical safety – from nuanced differences in ingestion methods to the rise in stimulated reporting due to Covid-19. Fraser underscores the critical necessity for collaboration within PV, the pitfalls of generic solutions, and the delicate balance of prudent spending and innovative problem-solving. Don't miss this opportunity to tap into Fraser’s vast knowledge and insights - perfect for anyone involved or interested in the world of pharmacovigilance.

Welcome to Truliant Talks, your definitive source for the world of pharmacovigilance amd risk management.As we enter an era defined by innovation and technological advancement, Truliant Talks is proud to announce a new podcast series, 'Innovation and the Future of Pharmacovigilance'.This holistic series will tackle every perspective of pharmacovigilance - from the role of regulators, the importance of vendors, to embracing AI, data privacy, and much more.We'll feature leaders, innovators, and visionaries - the people shaping pharmacovigilance. They'll share their experiences, insights, tips, and perhaps, a guess or two about what the future holds.Join us on this journey. The future begins on the 30th of October, available on all major podcast platforms.